Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098657 | 1.00 | SLC6A4 (0.46) | SLC6A4IDO1DRD2CHRNB2CHRNA7 | |
| SCHEMBL4098671 | 0.83 | SLC6A4 (0.50) | SLC6A4IDO1DRD2HTR2ASLC6A2 | |
| SCHEMBL4098677 | 0.83 | SLC6A4 (0.50) | SLC6A4IDO1DRD2HTR2ASLC6A2 | |
| SCHEMBL4098654 | 0.80 | IDO1 (0.46) | SLC6A4IDO1DRD2HTR2AHTR1A | |
| SCHEMBL4098650 | 0.80 | IDO1 (0.46) | SLC6A4IDO1DRD2HTR2AHTR1A | |
| SCHEMBL13620096 | 0.78 | HTR2A (0.48) | SLC6A4IDO1HTR2AHTR1ADRD1 | |
| SCHEMBL4103244 | 0.77 | HTR2A (0.47) | SLC6A4IDO1HTR2AHTR1ADRD1 | |
| SCHEMBL4103239 | 0.77 | HTR2A (0.47) | SLC6A4IDO1HTR2AHTR1ADRD1 | |
| SCHEMBL4100331 | 0.76 | HTR2A (0.51) | SLC6A4IDO1HTR2AHTR1ADRD1 | |
| SCHEMBL4100338 | 0.76 | HTR2A (0.51) | SLC6A4IDO1HTR2AHTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| WO-2009106559-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106559-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| CN-101472890-A | 3- (1H-indol- 3-ydindan-1-ylamine derivatives for the treatment of depression and anxiety | LUNDBECK & CO AS H (DK) | 2009-07-01 | — | — | CN | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
| WO-2008025361-A1 | 3-(1H-INDOL-3-YL) INDAN-1-YLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | OPRL1, HTR2C, SLC6A3 | SLC6A4 5/4885IDO1 11/4885DRD2 20/4885 |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | GPR119, INSR, IRS1 | SLC6A4 215/4885IDO1 19/4885DRD2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.